BRAF mutation in papillary thyroid microcarcinoma: The promise of better risk management

Annals of Surgical Oncology

Volumn 16, Issue 4, 2009, Pages 801-803

  Xing, Mingzhao ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; RADIOACTIVE IODINE;

ARTICLE; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CONSERVATIVE TREATMENT; GENE MUTATION; GENE SILENCING; HUMAN; LYMPH NODE METASTASIS; NECK DISSECTION; PAPILLARY THYROID MICROCARCINOMA; PARATHYROID DISEASE; PROGNOSIS; RADIOSURGERY; RECURRENT LARYNGEAL NERVE PALSY; RISK MANAGEMENT; THYROID CARCINOMA; THYROIDECTOMY; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA, PAPILLARY; HUMANS; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; RISK MANAGEMENT; THYROID NEOPLASMS;

EID: 62149143358     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-008-0298-z     Document Type: Article

References (24)

1. Lloyd R, DeLellis R, Heitz P, Eng C. World Health Organization classification of tumours: pathology and genetics of tumours of the endocrine organs. Lyon, France: IARC Press International Agency for Research on Cancer; 2004.
2. RL Witt 2008 Initial surgical management of thyroid cancer Surg Oncol Clin N Am. 17 71 91
3. AP Brown J Chen YJ Hitchcock A Szabo DC Shrieve JD Tward 2008 The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer J Clin Endocrinol Metab. 93 504 515
4. Y Ito T Uruno K Nakano Y Takamura A Miya K Kobayashi 2003 An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid Thyroid. 13 381 387
5. EL Mazzaferri 2006 Managing small thyroid cancers JAMA. 295 2179 2182
6. EL Mazzaferri 2007 Management of low-risk differentiated thyroid cancer Endocr Pract. 13 498 512
7. ID Hay 2007 Management of patients with low-risk papillary thyroid carcinoma Endocr Pract. 13 521 533
8. H Yamashita S Noguchi N Murakami M Toda S Uchino S Watanabe 1999 Extracapsular invasion of lymph node metastasis. A good indicator of disease recurrence and poor prognosis in patients with thyroid microcarcinoma Cancer. 86 842 849
9. I Sugitani Y Fujimoto 1999 Symptomatic versus asymptomatic papillary thyroid microcarcinoma: a retrospective analysis of surgical outcome and prognostic factors Endocr J. 46 209 216
10. SM Chow SC Law JK Chan SK Au S Yau WH Lau 2003 Papillary microcarcinoma of the thyroid-prognostic significance of lymph node metastasis and multifocality Cancer. 98 31 40
11. RM Reddy PW Grigsby JF Moley BL Hall 2006 Lymph node metastases in differentiated thyroid cancer under 2 cm Surgery. 140 1050 1054 discussion 1054-5
12. C Cappelli M Castellano M Braga E Gandossi I Pirola E De Martino 2007 Aggressiveness and outcome of papillary thyroid carcinoma (PTC) versus microcarcinoma (PMC): a mono-institutional experience J Surg Oncol. 95 555 560
13. M Xing 2007 BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications Endocr Rev. 28 742 762
14. R Elisei C Ugolini D Viola C Lupi A Biagini R Giannini 2008 BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study J Clin Endocrinol Metab. 93 3943 3949
15. M Xing WH Westra RP Tufano Y Cohen E Rosenbaum KJ Rhoden 2005 BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer J Clin Endocrinol Metab. 90 6373 6379
16. E Kebebew J Weng J Bauer G Ranvier OH Clark QY Duh 2007 The prevalence and prognostic value of BRAF mutation in thyroid cancer Ann Surg. 246 466 470
17. V Rodolico D Cabibi G Pizzolanti P Richiusa N Gebbia A Martorana 2007 BRAF(V600E) mutation and p27(kip1) expression in papillary carcinomas of the thyroid
18. C Lupi R Giannini C Ugolini A Proietti P Berti M Minuto 2007 Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma J Clin Endocrinol Metab. 92 4085 4090
19. Lee X, Gao M, Ji Y, Yu Y, Feng Y, Li Y, et al. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma. Ann Surg Oncol. 2009;2:240-5.
20. L Leenhardt P Grosclaude L Cherie-Challine 2004 Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? report from the French thyroid cancer committee Thyroid. 14 1056 1060
21. L Davies HG Welch 2006 Increasing incidence of thyroid cancer in the United States, 1973-2002 JAMA. 295 2164 2167
22. Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, et al., eds. SEER Cancer Statistics Review, 1975-2005, Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975-2005/, based on November 2007 SEER data submission, 2008.
23. I Sedliarou V Saenko D Lantsov T Rogounovitch H Nambra A Abrosimov 2004 The BRAFT1796A transversion is a prevalent mutational event in human thyroid microcarcinoma Int J Oncol. 25 1729 1735
24. C Ugolini R Giannini C Lupi G Salvatore P Miccoli A Proietti 2007 Presence of BRAF V600E in very early stages of papillary thyroid carcinoma Thyroid. 17 381 388